Therefore, this study systematically evaluates the efficacy and safety of various biologics—specifically IL-17, TNF-α, and IL-23 inhibitors—in patients with erythrodermic psoriasis (EP) by integrating available clinical evidence. Here, IL37 is linked to psoriasis.